Pfizer stokes rumor mill with plan to raise $5B in debt; Lilly's CGRP Emgality wins speedy review for cluster headaches
→ Pfizer $PFE is raising $5 billion in debt, and in this heated M&A environment, there’s quite a bit of buzz about what the money will be spent on. For the record, their statement says it will be used for general corporate uses plus debt restructuring. But that won’t stop the rumors on Twitter.
→ Lilly’s $LLY migraine drug is up for another approval. The treatment Emgality — one of the crop of recently approved CGRP inhibitors used for migraine prevention — has been granted priority review by the FDA to prevent episodic cluster headaches in adults. The under-recognized and often misdiagnosed disorder has no FDA-approved preventative treatments so far.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.